Company

Terns Pharmaceuticals, Inc.

Headquarters: Foster City, CA, United States

Employees: 41

CEO: Mr. Senthil Vel Sundaram

NASDAQ: TERN -5.25%

Market Cap

$459.2 Million

USD as of July 1, 2024

Market Cap History

Terns Pharmaceuticals, Inc. market capitalization over time

Evolution of Terns Pharmaceuticals, Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Terns Pharmaceuticals, Inc.

Detailed Description

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

Terns Pharmaceuticals, Inc. has the following listings and related stock indices.


Stock: NASDAQ: TERN wb_incandescent

Details

Headquarters:

1065 East Hillsdale Boulevard

Suite 100

Foster City, CA 94404

United States

Phone: 650 525 5535

Fax: 650 275 4395